



L4 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2001 ACS  
 AN 1993:560315 CAPLUS  
 DN 119:160315  
 TI Preparation of 4-amino-5-pyrimidinecarboxylic acids as ulcer inhibitors  
 IN Shimamura, Hiroshi; Terajima, Koji; Kawase, Akito; Ishizuka, Yasuhiro;  
 Kimura, Isami; Kamya, Akyoshi; Kataoka, Mikiko; Sato, Makoto  
 PA Morishita Ruseru Kk, Japan  
 SO Jpn. Kokai Tokkyo Koho, 24 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05112559	A2	19930507	JP 1991-299822	19911018
OS MARPAT 119:160315				
GI				



AB The title compds. I [R1, R2 = H, lower (halo)alkyl, lower alkoxy, halo;  
 R3 = NR5R6, .gtreq.1 N-contg. (substituted) (un)satd. heterocycl; R4 = H,  
 lower alkyl; R5, R6 = H, lower (alkoxy)alkyl, alkenyl, or alkynyl,  
 cycloalkyl, hydroxylalkyl, (substituted) Ph or benzyl; X = NR7, O, S; R7 =  
 H, lower alkyl; n = 0-2; if R1 = R2 = H, X = NH, and n = 1, then R3  
 .noteq. NMe2, NEtMe, nor morpholino] or their salts are prep'd. I (R1 =  
 R2 = H, R3 = Cl, R4 = Et, X = NH, n = 0) (prepn. given) in THF was treated  
 with aq. MeNH2 at room temp. for 1 h to give 89% I (R1 = R2 = H, R3 =  
 NHMe, R4 = Et, X = NH, n = 0). I (R1 = Me, R2 = H, R3 = NMe2, R4 = Et, X  
 = NH, n = 1) (II) showed 92% inhibition of acute gastric mucosal damage  
 caused by EtOH, vs. 90%, for omeprazole. A tablet contg. II was  
 formulated.  
 IT 150065-44-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and amination of)  
 RN 150065-44-4 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-[(1-methyl-1H-benzimidazol-2-  
 yl)thiomethyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 150065-33-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and chlorination of)

RN 150065-33-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-2-[(1-methyl-1H-benzimidazol-2-yl)thiomethyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 150064-45-2P 150065-20-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as ulcer inhibitor)

RN 150064-45-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(dimethylamino)-2-[(1-methyl-1H-benzimidazol-2-yl)thiomethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 150065-20-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(dimethylamino)-2-[(1-methyl-1H-benzimidazol-2-yl)sulfinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

09/743483

